11 results on '"Heine, Renaud"'
Search Results
2. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands
- Author
-
Heine, Renaud J.S.D., Mathijssen, Ron H.J., Verbeek, Floor A.J., Van Gils, Chantal, and Uyl-de Groot, Carin A.
- Published
- 2024
- Full Text
- View/download PDF
3. Variation in care for patients presenting with hip fracture in six high‐income countries: A cross‐sectional cohort study.
- Author
-
Burrack, Nitzan, Hatfield, Laura A., Bakx, Pieter, Banerjee, Amitava, Chen, Yu‐Chin, Fu, Christina, Godoy Junior, Carlos, Gordon, Michal, Heine, Renaud, Huang, Nicole, Ko, Dennis T., Lix, Lisa M., Novack, Victor, Pasea, Laura, Qiu, Feng, Stukel, Therese A., Uyl‐de Groot, Carin, Ravi, Bheeshma, Al‐Azazi, Saeed, and Weinreb, Gabe
- Subjects
INTERNAL fixation in fractures ,LENGTH of stay in hospitals ,DEVELOPED countries ,TOTAL hip replacement ,CROSS-sectional method ,HIP fractures ,RETROSPECTIVE studies ,ACQUISITION of data ,HEMIARTHROPLASTY ,PATIENT readmissions ,COMPARATIVE studies ,OSTEOPOROSIS ,MEDICAL records ,HOSPITAL care ,DESCRIPTIVE statistics ,RESEARCH funding ,PATIENT care ,LONGEVITY ,LONGITUDINAL method ,OLD age - Abstract
Background: Hip fractures are costly and common in older adults, but there is limited understanding of how treatment patterns and outcomes might differ between countries. Methods: We performed a retrospective serial cross‐sectional cohort study of adults aged ≥66 years hospitalized with hip fracture between 2011 and 2018 in the US, Canada, England, the Netherlands, Taiwan, and Israel using population‐representative administrative data. We examined mortality, hip fracture treatment approaches (total hip arthroplasty [THA], hemiarthroplasty [HA], internal fixation [IF], and nonoperative), and health system performance measures, including hospital length of stay (LOS), 30‐day readmission rates, and time‐to‐surgery. Results: The total number of hip fracture admissions between 2011 and 2018 ranged from 23,941 in Israel to 1,219,696 in the US. In 2018, 30‐day mortality varied from 3% (16% at 1 year) in Taiwan to 10% (27%) in the Netherlands. With regards to processes of care, the proportion of hip fractures treated with HA (range 23%–45%) and THA (0.2%–10%) differed widely across countries. For example, in 2018, THA was used to treat approximately 9% of patients in England and Israel but less than 1% in Taiwan. Overall, IF was the most common surgery performed in all countries (40%–60% of patients). IF was used in approximately 60% of patients in the US and Israel, but only 40% in England. In 2018, rates of nonoperative management ranged from 5% of patients in Taiwan to nearly 10% in England. Mean hospital LOS in 2018 ranged from 6.4 days (US) to 18.7 days (England). The 30‐day readmission rate in 2018 ranged from 8% (in Canada and the Netherlands) to nearly 18% in England. The mean days to surgery in 2018 ranged from 0.5 days (Israel) to 1.6 days (Canada). Conclusions: We observed substantial between‐country variation in mortality, surgical approaches, and health system performance measures. These findings underscore the need for further research to inform evidence‐based surgical approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Differences in Treatment Patterns and Outcomes of Acute Myocardial Infarction for Low- and High-Income Patients in 6 Countries
- Author
-
Landon, Bruce E., Hatfield, Laura A., Bakx, Pieter, Banerjee, Amitava, Chen, Yu Chin, Fu, Christina, Gordon, Michal, Heine, Renaud, Huang, Nicole, Ko, Dennis T., Lix, Lisa M., Novack, Victor, Pasea, Laura, Qiu, Feng, Stukel, Therese A., Uyl-De Groot, Carin, Yan, Lin, Weinreb, Gabe, Cram, Peter, Epidemiology and Data Science, AII - Cancer immunology, Health Economics (HE), and Health Technology Assessment (HTA)
- Subjects
General Medicine - Abstract
ImportanceDifferences in the organization and financing of health systems may produce more or less equitable outcomes for advantaged vs disadvantaged populations. We compared treatments and outcomes of older high- and low-income patients across 6 countries.ObjectiveTo determine whether treatment patterns and outcomes for patients presenting with acute myocardial infarction differ for low- vs high-income individuals across 6 countries.Design, Setting, and ParticipantsSerial cross-sectional cohort study of all adults aged 66 years or older hospitalized with acute myocardial infarction from 2013 through 2018 in the US, Canada, England, the Netherlands, Taiwan, and Israel using population-representative administrative data.ExposuresBeing in the top and bottom quintile of income within and across countries.Main Outcomes and MeasuresThirty-day and 1-year mortality; secondary outcomes included rates of cardiac catheterization and revascularization, length of stay, and readmission rates.ResultsWe studied 289 376 patients hospitalized with ST-segment elevation myocardial infarction (STEMI) and 843 046 hospitalized with non-STEMI (NSTEMI). Adjusted 30-day mortality generally was 1 to 3 percentage points lower for high-income patients. For instance, 30-day mortality among patients admitted with STEMI in the Netherlands was 10.2% for those with high income vs 13.1% for those with low income (difference, −2.8 percentage points [95% CI, −4.1 to −1.5]). One-year mortality differences for STEMI were even larger than 30-day mortality, with the highest difference in Israel (16.2% vs 25.3%; difference, −9.1 percentage points [95% CI, −16.7 to –1.6]). In all countries, rates of cardiac catheterization and percutaneous coronary intervention were higher among high- vs low-income populations, with absolute differences ranging from 1 to 6 percentage points (eg, 73.6% vs 67.4%; difference, 6.1 percentage points [95% CI, 1.2 to 11.0] for percutaneous intervention in England for STEMI). Rates of coronary artery bypass graft surgery for patients with STEMI in low- vs high-income strata were similar but for NSTEMI were generally 1 to 2 percentage points higher among high-income patients (eg, 12.5% vs 11.0% in the US; difference, 1.5 percentage points [95% CI, 1.3 to 1.8 ]). Thirty-day readmission rates generally also were 1 to 3 percentage points lower and hospital length of stay generally was 0.2 to 0.5 days shorter for high-income patients.Conclusions and RelevanceHigh-income individuals had substantially better survival and were more likely to receive lifesaving revascularization and had shorter hospital lengths of stay and fewer readmissions across almost all countries. Our results suggest that income-based disparities were present even in countries with universal health insurance and robust social safety net systems.
- Published
- 2023
5. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.
- Author
-
Thielen, Frederick W., Heine, Renaud J.S.D., Berg, Sibren van den, Ham, Renske M. T. ten, and Groot, Carin A. Uyl-de
- Subjects
- *
PRICES , *GENE therapy , *CELLULAR therapy , *PROFIT margins , *DRUG prices - Abstract
Drug prices are regarded as one of the most influential factors in determining accessibility and affordability to novel therapies. Cell and gene therapies such as OTL-200 (brand name: Libmeldy) and AVXS-101 (brand name: Zolgensma) with (expected) list prices of 3.0 million EUR and 1.9 million EUR per treatment, respectively, spark a global debate on the affordability of such therapies. The aim of this study was to use a recently published cost-based pricing model to calculate prices for cell and gene therapies, with OTL-200 and AVXS-101 as case study examples. Using the pricing model proposed by Uyl-de Groot and Löwenberg, we estimated a price for both therapies. We searched the literature and online public sources to estimate (i) research and development (R&D) expenses adjusted for risk of failure and cost of capital, (ii) the eligible patient population and (iii) costs of drug manufacturing to calculate a base-case price for OTL-200 and AVXS-101. All model input parameters were varied in a stepwise, deterministic sensitivity analysis and scenario analyses to assess their impact on the calculated prices. Prices for OTL-200 and AVXS-101 were estimated at 1 048 138 EUR and 380 444 EUR per treatment, respectively. In deterministic sensitivity analyses, varying R&D estimates had the greatest impact on the price for OTL-200, whereas for AVXS-101, changes in the profit margin changed the calculated price substantially. Highest prices in scenario analyses were achieved when assuming the lowest number of patients for OTL-200 and highest R&D expenses for AVXS-101. The lowest R&D expenses scenario resulted in lowest prices for either therapy. Our results show that, using the proposed model, prices for both OTL-200 and AVXS-101 lie substantially below the currently (proposed) list prices for both therapies. Nevertheless, the uncertainty of the used model input parameters is considerable, which translates in a wide range of estimated prices. This is mainly because of a lack of transparency from pharmaceutical companies regarding R&D expenses and the costs of drug manufacturing. Simultaneously, the disease indications for both therapies remain heavily understudied in terms of their epidemiological profile. Despite the considerable variation in the estimated prices, our results may support the public debate on value-based and cost-based pricing models, and on "fair" drug prices in general. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach.
- Author
-
Rabbe, Stefan, Möllenkamp, Meilin, Pongiglione, Benedetta, Blommestein, Hedwig, Wetzelaer, Pim, Heine, Renaud, and Schreyögg, Jonas
- Abstract
Variation in healthcare utilization has been discussed extensively, with many studies showing that variation exists, but fewer studies investigating the underlying factors. In our study, we used a logistic multilevel‐model at the patient, hospital, and regional levels to investigate (i) the levels to which variation could be attributed and (ii) the hospital and regional factors associated with treatment decisions. To do so, we used hospital discharge records for the years 2012–2016 in Germany and Italy and for 2014–2016 in the Netherlands combined with hospital and regional characteristics in nine case studies. We used a theoretical framework to categorize these case studies into effective, preference‐sensitive, and supply‐sensitive care. Our results suggest that most variation in the treatment decision can be attributed to the hospital level (e.g., case volume), whereas only a minor part is explained by regional characteristics. Italy had the highest share attributable to the regional level, whereas the Netherlands had the lowest. We observed less variation for procedures in the effective‐care category compared to the preference‐ and supply‐sensitive categories. Although our results were heterogeneous, we identified patterns in line with the theoretical framework for treatment categories, underlining the need to address variation differently depending on the category in question. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
- Author
-
Heine, Renaud, Thielen, Frederick W., Koopmanschap, Marc, Kersten, Marie José, Einsele, Hermann, Jaeger, Ulrich, Sonneveld, Pieter, Sierra, Jorge, Smand, Carin, Uyl-de Groot, Carin A., Universitat Autònoma de Barcelona, Health Technology Assessment (HTA), General Practice, Hematology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and Quality of Life
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,Chronic lymphocytic leukemia ,MEDLINE ,Treatment options ,Health technology ,medicine.disease ,Chimeric antigen receptor ,Article ,SDG 3 - Good Health and Well-being ,Internal medicine ,Health care ,Medicine ,media_common.cataloged_instance ,Diseases of the blood and blood-forming organs ,European union ,RC633-647.5 ,business ,Intensive care medicine ,health care economics and organizations ,media_common - Abstract
Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology.
- Published
- 2021
8. Good practice physical activity programs for older adults in EU
- Author
-
Heine, Renaud, Pavlova, Milena, Tambor, Marzena, Groot, Wim, Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care, Promovendi PHPC, TIER TA, and RS: FSE TA-TIER
- Subjects
education - Abstract
Health Promotion and Prevention of Risk – Action for Seniors PROJECT POLICY BRIEF 5
- Published
- 2016
9. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe.
- Author
-
Uyl-de Groot, Carin A., Heine, Renaud, Krol, Marieke, and Verweij, Jaap
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER patients , *MEDICAL records , *TUMORS , *DRUG approval , *RETROSPECTIVE studies , *IPILIMUMAB , *DESCRIPTIVE statistics , *INVESTIGATIONAL drugs , *ABIRATERONE acetate , *ACQUISITION of data methodology - Abstract
Background. Many new cancer medicines have been developed that can improve patients' outcomes. However, access to these agents comes later in Europe than in the United States (US). The aim of this study is to assess the access in Europe to newly registered cancer drugs and to get more insight in the implications of these variations for patients. Methods. A retrospective database study was conducted. Analyses involved 12 cancer drugs and 28 European countries in the period 2011–2018. Time to patient access, speed of drug uptake, and the potential loss of life years due to a delay in access have been studied. Results. Marketing approval for the cancer drugs came on average 242 days later in Europe than in the US, and actual patient access varied extensively across Europe. The average time to market in Europe was 403 days (range 17–1187 days). The delay in patient access of ipilimumab and abiraterone may have led to a potential loss of more than 30,000 life years. Conclusion. It takes a long time for patients to get access to newly registered cancer drugs and there is great variation in access. The health outcomes can be substantially improved by faster processes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Differences in Treatment Patterns and Outcomes of Acute Myocardial Infarction for Low- and High-Income Patients in 6 Countries.
- Author
-
Landon BE, Hatfield LA, Bakx P, Banerjee A, Chen YC, Fu C, Gordon M, Heine R, Huang N, Ko DT, Lix LM, Novack V, Pasea L, Qiu F, Stukel TA, Uyl-de Groot C, Yan L, Weinreb G, and Cram P
- Subjects
- Humans, Coronary Artery Bypass economics, Coronary Artery Bypass statistics & numerical data, Cross-Sectional Studies, Non-ST Elevated Myocardial Infarction economics, Non-ST Elevated Myocardial Infarction epidemiology, Non-ST Elevated Myocardial Infarction mortality, Non-ST Elevated Myocardial Infarction therapy, ST Elevation Myocardial Infarction economics, ST Elevation Myocardial Infarction epidemiology, ST Elevation Myocardial Infarction mortality, ST Elevation Myocardial Infarction therapy, Treatment Outcome, Socioeconomic Factors, Poverty economics, Poverty statistics & numerical data, Aged, Hospitalization economics, Hospitalization statistics & numerical data, Patient Readmission economics, Patient Readmission statistics & numerical data, Myocardial Revascularization economics, Myocardial Revascularization statistics & numerical data, Cardiac Catheterization economics, Cardiac Catheterization statistics & numerical data, Length of Stay economics, Length of Stay statistics & numerical data, Internationality, Myocardial Infarction economics, Myocardial Infarction epidemiology, Myocardial Infarction mortality, Myocardial Infarction therapy
- Abstract
Importance: Differences in the organization and financing of health systems may produce more or less equitable outcomes for advantaged vs disadvantaged populations. We compared treatments and outcomes of older high- and low-income patients across 6 countries., Objective: To determine whether treatment patterns and outcomes for patients presenting with acute myocardial infarction differ for low- vs high-income individuals across 6 countries., Design, Setting, and Participants: Serial cross-sectional cohort study of all adults aged 66 years or older hospitalized with acute myocardial infarction from 2013 through 2018 in the US, Canada, England, the Netherlands, Taiwan, and Israel using population-representative administrative data., Exposures: Being in the top and bottom quintile of income within and across countries., Main Outcomes and Measures: Thirty-day and 1-year mortality; secondary outcomes included rates of cardiac catheterization and revascularization, length of stay, and readmission rates., Results: We studied 289 376 patients hospitalized with ST-segment elevation myocardial infarction (STEMI) and 843 046 hospitalized with non-STEMI (NSTEMI). Adjusted 30-day mortality generally was 1 to 3 percentage points lower for high-income patients. For instance, 30-day mortality among patients admitted with STEMI in the Netherlands was 10.2% for those with high income vs 13.1% for those with low income (difference, -2.8 percentage points [95% CI, -4.1 to -1.5]). One-year mortality differences for STEMI were even larger than 30-day mortality, with the highest difference in Israel (16.2% vs 25.3%; difference, -9.1 percentage points [95% CI, -16.7 to -1.6]). In all countries, rates of cardiac catheterization and percutaneous coronary intervention were higher among high- vs low-income populations, with absolute differences ranging from 1 to 6 percentage points (eg, 73.6% vs 67.4%; difference, 6.1 percentage points [95% CI, 1.2 to 11.0] for percutaneous intervention in England for STEMI). Rates of coronary artery bypass graft surgery for patients with STEMI in low- vs high-income strata were similar but for NSTEMI were generally 1 to 2 percentage points higher among high-income patients (eg, 12.5% vs 11.0% in the US; difference, 1.5 percentage points [95% CI, 1.3 to 1.8 ]). Thirty-day readmission rates generally also were 1 to 3 percentage points lower and hospital length of stay generally was 0.2 to 0.5 days shorter for high-income patients., Conclusions and Relevance: High-income individuals had substantially better survival and were more likely to receive lifesaving revascularization and had shorter hospital lengths of stay and fewer readmissions across almost all countries. Our results suggest that income-based disparities were present even in countries with universal health insurance and robust social safety net systems.
- Published
- 2023
- Full Text
- View/download PDF
11. Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study.
- Author
-
Cram P, Hatfield LA, Bakx P, Banerjee A, Fu C, Gordon M, Heine R, Huang N, Ko D, Lix LM, Novack V, Pasea L, Qiu F, Stukel TA, de Groot CU, Yan L, and Landon B
- Subjects
- Adult, Cohort Studies, Cross-Sectional Studies, Developed Countries, Hospital Mortality, Hospitals, Humans, Ontario, Retrospective Studies, Risk Factors, Treatment Outcome, United States epidemiology, Myocardial Infarction epidemiology, Myocardial Infarction surgery, Non-ST Elevated Myocardial Infarction diagnosis, Non-ST Elevated Myocardial Infarction therapy, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction therapy
- Abstract
Objectives: To compare treatment and outcomes for patients admitted to hospital with a primary diagnosis of ST elevation or non-ST elevation myocardial infarction (STEMI or NSTEMI) in six high income countries with very different healthcare delivery systems., Design: Retrospective cross sectional cohort study., Setting: Patient level administrative data from the United States, Canada (Ontario and Manitoba), England, the Netherlands, Israel, and Taiwan., Participants: Adults aged 66 years and older admitted to hospital with STEMI or NSTEMI between 1 January 2011 and 31 December 2017., Outcomes Measures: The three categories of outcomes were coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft surgery), mortality, and efficiency (hospital length of stay and 30 day readmission). Rates were standardised to the age and sex distribution of the US acute myocardial infarction population in 2017. Outcomes were assessed separately for STEMI and NSTEMI. Performance was evaluated longitudinally (over time) and cross sectionally (between countries)., Results: The total number of hospital admissions ranged from 19 043 in Israel to 1 064 099 in the US. Large differences were found between countries for all outcomes. For example, the proportion of patients admitted to hospital with STEMI who received percutaneous coronary intervention in hospital during 2017 ranged from 36.9% (England) to 78.6% (Canada; 71.8% in the US); use of percutaneous coronary intervention for STEMI increased in all countries between 2011 and 2017, with particularly large rises in Israel (48.4-65.9%) and Taiwan (49.4-70.2%). The proportion of patients with NSTEMI who underwent coronary artery bypass graft surgery within 90 days of admission during 2017 was lowest in the Netherlands (3.5%) and highest in the US (11.7%). Death within one year of admission for STEMI in 2017 ranged from 18.9% (Netherlands) to 27.8% (US) and 32.3% (Taiwan). Mean hospital length of stay in 2017 for STEMI was lowest in the Netherlands and the US (5.0 and 5.1 days) and highest in Taiwan (8.5 days); 30 day readmission for STEMI was lowest in Taiwan (11.7%) and the US (12.2%) and highest in England (23.1%)., Conclusions: In an analysis of myocardial infarction in six high income countries, all countries had areas of high performance, but no country excelled in all three domains. Our findings suggest that countries could learn from each other by using international comparisons of patient level nationally representative data., Competing Interests: Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the US National Institute on Aging, ICES, Ontario Ministry of Health and Long term Care, Canadian Institute for Health Information for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.